enquiry@dsij.in |+91 9240904920
SENSEX512.34
82,104.790.63%

Aurobindo Pharma gains from Lannett integration and broad-based formulations growth

Aurobindo Pharma Ltd.

Broker Recommendation:

BUY

Broker: Geojit Investments Limited

16 Nov 2026

Sector: Healthcare

Original PDF
Reco. Price

₹1,829

CMP

₹1,788

Target

₹2,111

Upside

15.42%

Investment View and Target Price

Geojit Investments Limited retained its BUY rating on Aurobindo Pharma Ltd. in its November 16, 2026 Q2FY27 result update and revised its target price to Rs 2,111.

The broker’s positive view reflects broad-based momentum in core formulations, growth in key geographies, progress in differentiated businesses and potential medium-term growth from biosimilars, biologics contract manufacturing and Contract Development and Manufacturing Organisation initiatives.

Q2FY27 Financial Performance

Aurobindo Pharma reported record consolidated revenue of Rs 10,263 crore in Q2FY27, up 23.9 per cent YoY and 12.2 per cent QoQ. Growth was supported by formulations and active pharmaceutical ingredients, consolidation of Lannett Company LLC, strong injectables momentum and differentiated product launches.

Metric Q2FY27 Growth
US formulations revenue Rs 4,555 crore 25.2 per cent YoY
Europe revenue Rs 3,161 crore 27.5 per cent YoY
EBITDA Rs 2,156 crore 28.5 per cent YoY; 14.6 per cent QoQ
EBITDA margin 21.0 per cent Up 70 basis points YoY and 40 basis points QoQ
Adjusted PAT Rs 1,126 crore 32.8 per cent YoY
Adjusted EPS Rs 19.6 34.0 per cent YoY

US formulations revenue increased 25.2 per cent YoY to Rs 4,555 crore, aided by Lannett integration, volume expansion and the ramp-up of injectables. Europe revenue grew 27.5 per cent YoY to Rs 3,161 crore on robust execution, portfolio expansion and improved supply-chain support.

Geojit attributed the margin improvement to scale benefits, a stronger product mix, manufacturing efficiencies and improving operating leverage. For H1FY27, revenue grew 20.2 per cent YoY to Rs 19,414 crore, EBITDA increased 23.0 per cent to Rs 4,037 crore and adjusted PAT rose 31.5 per cent to Rs 2,199 crore.

Mid_Bridge.webp

Capturing Growth Beyond Large Caps

Mid-cap companies can offer a compelling mix of growth and scalability. DSIJ's Mid Bridge identifies researched mid-cap opportunities with the potential to participate in emerging business trends.

Management Commentary and Business Developments

Management reiterated FY27 guidance for double-digit revenue growth, EBITDA margin above 21 per cent and EBITDA exceeding Rs 8,000 crore.

  • The US$245.7 million acquisition of Lannett Company LLC had been completed, expanding Aurobindo Pharma’s US portfolio and manufacturing capabilities.
  • The acquisition of A1 Biochem Labs strengthens integrated contract research, development and manufacturing capabilities.
  • Product progress included the launch of gAdvair and approval for gQVAR.
  • The China oral solid dosage facility had commercialised about 15 products and management expected it to break even during the current quarter.
  • The Raleigh facility received Voluntary Action Indicated status and is expected to support inhalation, transdermal and dermatology products over coming quarters.
  • Management remained confident of sustaining double-digit growth in Europe.

Revised Estimates and Valuation

Geojit increased its FY27E and FY28E estimates after the quarterly performance.

Metric FY27E FY28E
Revenue Rs 40,028 crore, raised 6.3 per cent Rs 44,826 crore, raised 10.1 per cent
EBITDA Rs 8,582 crore, raised 9.9 per cent Rs 9,764 crore, raised 12.9 per cent
EBITDA margin 21.4 per cent 21.8 per cent

The broker expects EBITDA margin to expand from 20.4 per cent in FY26A to 21.4 per cent in FY27E and 21.8 per cent in FY28E. Its target price is based on 22 times FY28E adjusted EPS.

Key Risk

Further regulatory action at the Lannett facility remains the key monitorable risk to the investment thesis.

Download Original Research Report

Disclaimer: This is a summary of a research report published by the broker/research house identified above. The views, recommendations, target prices and estimates are those of the respective broker and do not represent DSIJ investment advice. The summary may be AI-assisted, hence please refer to the original report for complete details, disclosures and risks.